Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

“Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?” C. Vogelmeier, A. D'Urzo, R. Pauwels†, J.M. Merino, M. Jaspal, S. Boutet, I. Naya and D. Price. Eur Respir J 2005; 26: 819–828.

European Respiratory Journal 2011 38: 491; DOI: 10.1183/09031936.60028305
  • Article
  • Info & Metrics
  • PDF
Loading

Since publication of the above manuscript, the authors have become aware of two areas that require adjustment.

In the Safety section of the manuscript (Results, Safety, fourth sentence), patients who prematurely discontinued study treatment due to adverse events but who remained in the study and continued to be seen and assessed by the investigator during subsequent scheduled study visits, were incorrectly described as having discontinued the study. This sentence should have been presented as follows: “Although a comparable number of patients discontinued study treatment due to AEs (27 budesonide/formoterol patients versus 28 salmeterol/fluticasone patients), a greater number of salmeterol/fluticasone patients withdrew owing to asthma versus budesonide/formoterol patients (11 versus three patients, respectively).”

In addition to the above, the following should have been presented as the last paragraph in the Study design section (Methods, Study design):

“Patients discontinuing study treatment prematurely were asked to complete their notebook for the remainder of the 12-month study period and to attend the remaining scheduled study visits. Patients who agreed to this were regarded as having discontinued the study treatment but not as having discontinued the study. At discontinuation of study treatment, patients were assessed by the investigator, asked about the reason for discontinuation and any adverse events were followed up as necessary. Adverse event data collected for patients discontinuing study treatment were limited to serious adverse events. Patients discontinuing the study permanently who did not agree to completing the notebook and assessments further to discontinuing study treatment, were recorded as having discontinued the study.”

The authors apologise for these omissions.

  • ©ERS 2011
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 2 Table of Contents
European Respiratory Journal: 38 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
“Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?” C. Vogelmeier, A. D'Urzo, R. Pauwels†, J.M. Merino, M. Jaspal, S. Boutet, I. Naya and D. Price. Eur Respir J 2005; 26: 819–828.
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
“Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?” C. Vogelmeier, A. D'Urzo, R. Pauwels†, J.M. Merino, M. Jaspal, S. Boutet, I. Naya and D. Price. Eur Respir J 2005; 26: 819–828.
European Respiratory Journal Aug 2011, 38 (2) 491; DOI: 10.1183/09031936.60028305

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
“Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?” C. Vogelmeier, A. D'Urzo, R. Pauwels†, J.M. Merino, M. Jaspal, S. Boutet, I. Naya and D. Price. Eur Respir J 2005; 26: 819–828.
European Respiratory Journal Aug 2011, 38 (2) 491; DOI: 10.1183/09031936.60028305
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • “Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash, et al. Eur Respir J 2022; 60: 2101814
  • “Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis.” S.M. Kawut, M.J. Krowka, K.A. Forde, N. Al-Naamani, K.L. Krok, M. Patel, C.R. Bartoli, M. Doyle, J. Moutchia, G. Lin, J.K. Oh, C.D. Mottram, P.D. Scanlon and M.B. Fallon for the Pulmonary Vascular Complications of Liver Disease Study Group. Eur Respir J 2022; 60: 2102304.
  • “Gut microbiota mediate vascular dysfunction in a murine model of sleep apnoea: effect of probiotics.” M. Badran, A. Khalyfa, A.C. Ericsson, C. Puech, Z. McAdams, S.B. Bender and D. Gozal. Eur Respir J 2023; 61: 2200002.
Show more Author Correction

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society